Zusammenfassung
Patienten mit Krebserkrankungen weisen eine hohe Rate an komorbiden depressiven und Angststörungen auf, die paradigmatisch in einen komplexen biopsychosozialen Kontext gestellt werden müssen. Bei der Diagnosestellung sind einige konzeptuelle Herausforderungen zu meistern. Die psychischen Komorbiditäten bedeuten nicht nur ein höheres subjektives Leiden, ein reduziertes Coping, mögliche negative Interferenzen mit somatischen Therapien und Rehabilitationen, eine stärker beeinträchtigte Lebensqualität sowie höhere Grade an psychosozialer Behinderung. Sie schließen auch ein höheres somatisches Morbiditäts- und Mortalitätsrisiko im weiteren Verlauf ein. Die vielfältigen psychologischen, psychosozialen, morbogenen und therapiebezogenen Stressoren müssen aufeinander bezogen und auf gemeinsame neurobiologische, v. a. neuroendokrine, neuroinflammatorische Vermittlungsmechanismen hin reflektiert werden. Hierbei sind stets mehrfache psychosomatische, somatopsychische und somatosomatische Effekte zu beachten. Es existieren evidenzbasierte psychotherapeutische und psychopharmakologische Ansätze für eine integrative Behandlung der komorbiden depressiven und Angststörungen.
Summary
Patients with cancer face a high risk of comorbid depressive and anxiety disorders that have to be paradigmatically considered within a complex biopsychosocial context. Several conceptual challenges have to be mastered in arriving at a correct clinical diagnosis. Coexistent affective and anxiety disorders in cancer patients include a more dramatic subjective suffering, reduced psychological coping, possible negative interference with somatic treatment and rehabilitation, impaired quality of life and higher grades of psychosocial disability. They may also lead to an overall increased risk of somatic morbidity, a more rapid progression of cancer and a higher cancer-related mortality in the course of the disease. Manifold psychological, psychosocial and existential, cancer and treatment-related stressors have to be considered with respect to common neurobiological, especially neuroendocrine and neuroinflammatory mechanisms. Complex psychosomatic, somatopsychic and somato-somatic effects must always be considered. Evidence-based approaches in psychotherapy and pharmacotherapy exist for the integrative treatment of comorbid depressive and anxiety disorders in cancer.
Literatur
Kapfhammer HP (2015) Psychische Störungen bei somatischen Krankheiten. In: Möller HJ, Laux G, Kapfhammer HP (Hrsg) Psychiatrie, Psychosomatik, Psychotherapie, 5. Aufl. Springer, Berlin (im Druck)
Levin TT, Alici Y (2010) Anxiety disorders. In: Holland JC, Breitbart W, Paul B. Jacobsen PB (Hrsg) Textbook of psycho-oncology, 2. Aufl. Oxford University Press, Oxford, S 324–331
Miller K, Massie MJ (2010) Depressive disorders. In: Holland JC, Breitbart W, Paul B. Jacobsen PB (Hrsg) Textbook of psycho-oncology, 2. Aufl. Oxford University Press, Oxford, S 311–318
Li M, Fitzgerald P, Rodin G (2012) Evidence-based treatment of depression in patients with cancer. J Clin Oncol 30:1187–1196
Tecuta L, Tomba E, Grandi S, Fava GA (2014) Demoralization: a systematic review on its clinical characterization. Psychol Med (Epub ahead of print)
Robinson S, Kissane DW, Brooker J, Burney S (2014) A Systematic review of the demoralization syndrome in individuals with progressive disease and cancer: a decade of research. J Pain Symptom Manage (Epub ahead of print)
Traeger L, Greer JA, Fernandez-Robles C et al (2012) Evidence-based treatment of anxiety in patients with cancer. J Clin Oncol 30:1197–1205
Kapfhammer HP (2014) Diagnostische Konzeptualisierung von Trauma- und Stressor-bezogenen Störungen im DSM 5. Nervenarzt 85:553–563
Andersen BL, DeRubeis RJ, Berman BS et al (2014) Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American Society of Clinical Oncology guideline adaptation. J Clin Oncol 32:1605–1619
Walker J, Holm Hansen C, Martin P et al (2013) Prevalence of depression in adults with cancer: a systematic review. Ann Oncol 24:895–900
Mitchell AJ, Chan M, Bhatti H et al (2011) Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 12:160–174
Boyes AW, Girgis A, D’Este CA et al (2013) Prevalence and predictors of the short-term trajectory of anxiety and depression in the first year after a cancer diagnosis: a population-based longitudinal study. J Clin Oncol 31:2724–2729
Mehnert A, Vehling S, Scheffold K et al (2013) Prävalenz von Anpassungsstörung, Akuter und Posttraumatischer Belastungsstörung sowie somatoformen Störungen bei Krebspatienten. Ein systematischer Literaturreview und Metaanalyse. Psychother Psychosom Med Psychol 63:466–472
Mehnert A, Brähler E, Faller H et al (2014) Four-week prevalence of mental disorders in patients with cancer across major tumor entities. J Clin Oncol 32:3540–3546
Kiserud CE, Dahl AA, Loge JH, Fosså SD (2014) Cancer survivorship in adults. Recent Results Cancer Res 197:103–120
Koch L, Jansen L, Brenner H, Arndt V (2013) Fear of recurrence and disease progression in long-term (≥ 5 years) cancer survivors – a systematic review of quantitative studies. Psychooncology 22:1–11
Mitchell AJ, Ferguson DW, Gill J et al (2013) Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. Lancet Oncol 14:721–732
Currier MB, Nemeroff CB (2014) Depression as a risk factor for cancer: from pathophysiological advances to treatment implications. Annu Rev Med 65:203–221
Penninx BW, Guralnik JM, Pahor M et al (1998) Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst 90:1888–1893
Gallo JJ, Armenian HK, Ford DE et al (2010) Major depression and cancer: the 13-year follow-up of the Baltimore epidemiologic catchment area sample (United States). Cancer Causes Control 11:751–758
Gross AL, Gallo JJ, Eaton WW (2010) Depression and cancer risk: 24 years of follow-up of the Baltimore Epidemiologic Catchment Area sample. Cancer Causes Control 21:191–199
Chida Y, Hamer M, Wardle J, Steptoe A (2008) Do stress-related psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol 5:466–475
Lillberg K, Verkasalo PK, Kaprio J et al (2003) Stressful life events and risk of breast cancer in 10,808 women: a cohort study. Am J Epidemiol 157:415–423
Hamer M, Chida Y, Molloy GJ (2009) Psychological distress and cancer mortality. J Psychosom Res 66:255–258
Satin JR, Linden W, Phillips MJ (2009) Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 115:5349–5361
Pinquart M, Duberstein PR (2010) Depression and cancer mortality: a meta-analysis. Psychol Med 40:1797–1810
Hem E, Loge JH, Haldorsen T, Ekeberg Ø (2004) Suicide risk in cancer patients from 1960 to 1999. J Clin Oncol 22:4209–4216
Rasic DT, Belik SL, Bolton JM et al (2008) Cancer, mental disorders, suicidal ideation and attempts in a large community sample. Psychooncology 17:660–667
Robson A, Scrutton F, Wilkinson L, MacLeod F (2010) The risk of suicide in cancer patients: a review of the literature. Psychooncology 19:1250–1258
Breitbart W, Rosenfeld B, Pessin H et al (2000) Depression, hopelessness, and desire for hastened death in terminally ill patients with cancer. JAMA 284:2907–2911
Garssen B (2004) Psychological factors and cancer development: evidence after 30 years of research. Clin Psychol Rev 24:315–338
Kangas M, Henry JL, Bryant RA (2005) Predictors of posttraumatic stress disorder following cancer. Health Psychol 24:579–585
Makrilia N, Indeck B, Syrigos K, Saif MW (2009) Depression and pancreatic cancer: a poorly understood link. J Pancreas 10:69–76
Miller AH (2009) Norman Cousins Lecture. Mechanisms of cytokine induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav Immun 23:149–158
Lutgendorf SK, Sood AK (2011) Biobehavioral factors and cancer progression: physiological pathways and mechanisms. Psychosom Med 73:724–730
Haroon E, Raison CL, Miller AH (2012) Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 37:137–162
Aldea M, Craciun L, Tomuleasa C, Crivii C (2014) The role of depression and neuroimmune axis in the prognosis of cancer patients. J BUON 19:5–14
Laird BJ, Boyd AC, Colvin LA, Fallon MT (2009) Are cancer pain and depression interdependent? A systematic review. Psychooncology 18:459–464
Brown LF, Kroenke K (2009) Cancer-related fatigue and its associations with depression and anxiety: a systematic review. Psychosomatics 50:440–447
Irwin MR (2013) Depression and insomnia in cancer: prevalence, risk factors, and effects on cancer outcomes. Curr Psychiatry Rep 15:404. doi:10.1007/s11920-013-0404-1
Roxburgh CS, McMillan DC (2014) Cancer and systemic inflammation: treat the tumour and treat the host. Br J Cancer 110:1409–1412
Seruga B, Zhang H, Bernstein LJ, Tannock IF (2008) Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 8:887–899
Benton TD, Blume J, Crits-Christoph P et al (2014) Depression and medical illness. In: Charney DS, Skalr P, Buxbaum JD, Nestler EJ (Hrsg) Neurobiology of mental illness, 4. Aufl. Oxford University Press, Oxford, S 496–507
Grassi L, Riba M (2012) Clinical psycho-oncology. An international perspective. Wiley-Blackwell, Chichester
Faller H, Schuler M, Richard M et al (2013) Effects of psycho-oncologic interventions on emotional distress and quality of life in adult patients with cancer: systematic review and meta-analysis. J Clin Oncol 31:782–793
Barrera I, Spiegel D (2014) Review of psychotherapeutic interventions on depression in cancer patients and their impact on disease progression. Int Rev Psychiatry 26:31–43
Fitzgerald P, Li M, Grassi L, Rodin G (2014) Pharmacotherapy of depression in cancer patients. In: Grassi L, Riba M (Hrsg) Psychopharmaclogy in oncology and palliatve care. Springer, Berlin, S 145–161
Rayner L, Price A, Evans A et al (2011) Antidepressants for the treatment of depression in palliative care: systematic review and meta-analysis. Palliat Med 25:36–51
Laoutidis ZG, Mathiak K (2013) Antidepressants in the treatment of depression/depressive symptoms in cancer patients: a systematic review and meta-analysis. BMC Psychiatry 13:140. doi:10.1186/1471-244X-13-140
Miguel C, Albuquerque E (2011) Drug interaction in psycho-oncology: antidepressants and antineoplastics. Pharmacology 88:333–339
Grassi L, Nanni MG, Uchitomi Y, Riba M (2011) Pharmacotherapy in people with cancer. In: Kissane DW, Maj M, Sartorius N (Hrsg) Depression and cancer. Wiley-Blackwell, Chichester, S 151–176
Einhaltung ethischer Richtlinien
Interessenkonflikt. H.P. Kapfhammer gibt an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kapfhammer, HP. Depressive und Angststörungen bei Krebserkrankungen. Nervenarzt 86, 291–301 (2015). https://doi.org/10.1007/s00115-014-4156-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00115-014-4156-x